



MEDI LIFESTYLE LIMITED

(Company Registration Number 201117734D)
(Incorporated in the Republic of Singapore on 26 July 2011)

STRATEGIC LAB LINK COLLABORATION AGREEMENT

The Board of Directors (the "**Board**" or "**Directors**") of Medi Lifestyle Limited (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that the Company's indirect wholly owned subsidiaries, HealthPro Pharma Pte Ltd ("**HPP**") and Healthpro Marketing Sdn. Bhd ("**HPM**") has signed a strategic lab link collaboration agreement (the "**Collaboration Agreement**") with FIOR Bioscience, LLC . ("**FIOR Bioscience**") together with Shine Bioscience, LLC ("**SBS**"), joining forces to accelerate stem cell therapy access in Asia. The Collaboration Agreement is focused on research and development ("**R&D**") on cutting-edge stem cell therapy products to revolutionize healthcare and advance regenerative medicine in the region.

The collaboration between HPP, HPM, SBS, and FIOR Bioscience is driven by a shared vision of improving preventive healthcare outcomes and expanding access to transformative stem cell therapies. By leveraging on the expertise and resources of each organization, this collaboration seeks to bring a wide range of innovative stem cell therapy products to medical professionals and patients throughout Asia, in particular for regenerative and beauty industries, and certain specific treatments such as Osteoarthritis.

As part of this collaboration, HPP and HPM shall be responsible for carrying out localised efficacy trials, clinical data management and registration of stem cell products within Asia while SBS, who is the exclusive distributor of FIOR Bioscience's stem-cell products, shall be responsible for providing clinical data, reports and protocols of the stem cell therapy products, to support and facilitate the trials carried out by HPP and HPM. FIOR Bioscience's products are FDA registered and the company is dedicated to advancing regenerative medicine by utilizing cutting-edge biomedical science and research to produce safe and effective postnatal stem cell biological medicine.

Patient safety and well-being are of paramount importance to HPP, HPM, SBS, and FIOR Bioscience. Each organization is committed to upholding the highest standards of quality, adhering to regulatory requirements, and ensuring ethical practices throughout the distribution and administration of the FDA-registered stem cell product in Asia.

Dato Ken Low, Executive Director & CEO of the Company, commented, "We will not only import and distribute existing FDA-registered stem cell therapy products but also spearhead localized research and development efforts, focusing on creating ground-breaking treatment solutions for preventive healthcare within the Asian population. By driving innovation and maintaining the highest safety and ethical standards, we are dedicated to ensuring the well-being and satisfaction of our patients."

Mr. David Kasteler, Managing Director of Shine Bioscience, LLC, commented, "We are immensely excited about the potential impact of this collaboration, as it represents a significant milestone in bringing accessible and effective stem cell therapies to Asia. By harnessing FIOR Bioscience's pioneering research capabilities and the patient-centric approach of Healthpro Pharma and Healthpro Marketing, we are committed to transforming healthcare and offering exceptional regenerative treatments to individuals throughout the region."

Shareholders and other investors are reminded to exercise caution while dealing in the shares of the Company. In the event that shareholders and other investors are in doubt when dealing in the shares of the Company, they should consult their bankers, stockbrokers, solicitors or other professional advisers.

The Company will make the appropriate announcements as and when there are material developments.

By Order of the Board

Dato' Low Koon Poh
Executive Chairman and Chief Executive Officer
15 August 2023

MEDIA CONTACT

For media queries, please contact;

MEDI LIFESTYLE Limited

Corporate Communications Department

Tel: +65 6299 9881

Jeysie Wong (Mobile +60 13 257 2787, Email: jeysie.wong@medi-lifestyle.com)

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.*

The contact person for the Sponsor is Ms Charmian Lim, at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, telephone: (65) 6232 3210.